Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183550 | 0.93 | BRD4 (0.37) | KDM4EHTR6L3MBTL1SMN1; SMN2BRD4 | |
| SCHEMBL28325700 | 0.90 | KDM4E (0.42) | KDM4EL3MBTL1POLBSMN1; SMN2HPGD | |
| SCHEMBL28325696 | 0.90 | GRM2 (0.38) | KDM4EHTR6HDAC8 | |
| SCHEMBL21474013 | 0.86 | HPGD (0.47) | KDM4EHTR6HPGDALDH1A1 | |
| SCHEMBL20183708 | 0.85 | KDM4E (0.44) | KDM4EL3MBTL1POLBSMN1; SMN2HPGD | |
| SCHEMBL20183760 | 0.85 | PDK4 (0.48) | KDM4EHTR6 | |
| SCHEMBL21459203 | 0.84 | KDM4E (0.38) | KDM4EL3MBTL1POLBHPGDBRD4 | |
| SCHEMBL20183527 | 0.81 | CNR2 (0.43) | HTR6HDAC8SMN1; SMN2ALDH1A1 | |
| SCHEMBL21459058 | 0.80 | KDM4E (0.45) | KDM4EL3MBTL1POLBSMN1; SMN2HPGD | |
| SCHEMBL20183646 | 0.79 | PDK4 (0.44) | HTR6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| EP-3563851-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3327004-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Fujifilm Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | BRD4, BRD1, BRD3 | KDM4E 1027/4885HTR6 4048/4885L3MBTL1 209/4885 |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | CXCL10, CCL5, CXCR3 | KDM4E 3906/4885HTR6 3185/4885L3MBTL1 1195/4885 |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | BRD4, BRD1, BRD3 | KDM4E 1027/4885HTR6 4048/4885L3MBTL1 209/4885 |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CXCL10, CCL5, CXCR3 | KDM4E 3906/4885HTR6 3185/4885L3MBTL1 1195/4885 |
| US-10633343-B2 | — | CXCL10, CCL5, CXCR3 | KDM4E 3627/4885HTR6 3849/4885L3MBTL1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.